DE
R&D Services for Industry

R&D Services for Industry

Culture dish with microorganisms under black light

Enzymes, microorganisms, bioprocesses

As a technology service provider and specialist in industrial biotechnology, we develop customized solutions for B2B. At our site in Zwingenberg, Germany, we develop and optimize application-specific, research-intensive solutions. Thanks to our in-depth knowledge of enzyme technology, strain development and bioprocess development as well as our many years of industry experience, we discuss with industry experts on an equal footing in order to find the best solutions.

R&D Services BRAIN Biotech Zwingenberg:
  • Enzyme technology
  • Production strain development
  • Bioprocess development

Bioinformatics forms a central element of our R&D expertise for faster and better solutions. In addition to our employees’ experience, we rely here on state-of-the-art technologies in the machine learning and artificial intelligence areas.

Glass tubes with colored liquids from extraction processes

Bioactive compounds

At the Potsdam site, our bioactive ingredient experts work on the discovery and development of small molecules and natural compounds, primarily for companies in the pharmaceutical, food and cosmetics industries.

F&E services at our Potsdam research site - Analyticon Discovery:
  • Bioactive compounds
  • Small molecules
  • Natural product candidate screening

We draw on a broad technology portfolio and do not limit ourselves to individual technologies to develop a good solution. It is the combination that makes us strong.

Dr. Alexander Pelzer - Vice President Head R&D BRAIN Biotech Zwingenberg

Basis of our R&D activities

Technology and methods not limited

Biotechnological research and the development of biotechnological processes and products form the basis of BRAIN Biotech's business activities. As early as 1999, production organisms, enzyme products and gene libraries were developed with the help of proprietary metagenome technology.

Today, our portfolio includes various patented specialty technologies that are reflected in our patent portfolio. One of these specialty technologies is the proprietary genome engineering technology (G-Dase E® and G-Dase M®, formerly BEC/BMC): a technique for the targeted and precise modification of DNA. We use the technology to accelerate strain development in customer projects, among other things.

  • Our Bioarchive contains around 53,000 comprehensively characterized microorganisms, isolated natural substances, chassis microorganism strains for the development of production organisms and genetic libraries with new enzymes and metabolic pathways.
  • Among other things, the subsidiary AnalytiCon Discovery GmbH, Potsdam, has built focused libraries accelerating early drug discovery.

All collections are being expanded in ongoing projects and enable the identification of previously uncharacterized enzymes and natural substances and new access to non-cultivable microorganisms.

Examples of successful research projects

Significant milestones achieved (as of July 2024)

  • Biological wound care: Clinical test phase 2a was successfully completed for the Aurase® enzyme.
  • Sustainable metal extraction in the circular economy: The "Gold from Waste Streams" project is being continued with an industrial partner.
  • Drug development: The active ingredient deucrictibant licensed out to the company Pharvaris for the treatment of hereditary angioedema (HAE) is showing promising progress in clinical development.